Pharm Res https://doi.org/10.1007/s11095-017-2337-6 RESEARCH PAPER Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer 1 1 1 1 1 1 1 Biki Gupta & Bijay Kumar Poudel & Shobha Regmi & Shiva Pathak & Hima Bindu Ruttala & Milan Gautam & Gyeong Jin An & 1 2 1 1 Jee-Heon Jeong & Han-Gon Choi & Chul Soon Yong & Jong Oh Kim Received: 20 September 2017 /Accepted: 20 December 2017 # Springer Science+Business Media, LLC, part of Springer Nature 2018 ABSTRACT the free drug cocktail. Moreover, well-defined early and late Purpose Lung cancer is the leading cause of cancer-related apoptosis were observed with clearly visible signs of apoptotic deaths. The aim of this study was to design solid lipid core nuclei. nanocapsules (SLCN) comprising a solid lipid core and a Conclusion PTX/ERL-SLCN could be employed as an op- PEGylated polymeric corona for paclitaxel (PTX) and erloti- timal approach for combination chemotherapy of NSCLC. nib (ERL) co-delivery to non-small cell lung cancer (NSCLC), . . and evaluate their physicochemical characteristics and in vitro KEY WORDS Erlotinib paclitaxel solid lipid core activity in NCI-H23 cells. nanocapsules non-smallcelllungcancer Methods PTX/ERL-SLCN were prepared by
Pharmaceutical Research – Springer Journals
Published: Mar 13, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud